Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Read this somewhere and how true it is.
Every stock I have has been down of late, yet I know what I own, so I rest easy and try to add to positions through the hard times. Never a straight line to money and you need to hang on through the volatility.
Therefore know what you own.
Found on Yahoo message board and is a good question:
Question:
"a synthetic oral endocannabinoid-mimetic" Why use a company concentrating on a synthetic version?
Answer:
In general a synthetic is prue so the FDA would have no problems given the green light on a product derived from an cannabinoid-mimetic, yet it will be hard for the FDA to pass any trial that uses a marijuana derived biotech base as it is illegal still in most of the world. Also from my understanding it works the same as THC without the psychoactive constituent of cannabis.
Corbus Pharmaceuticals CEO: Manmade Cannabinoids | Mad Money | CNBC
CNBC Television
1 week ago:
Published on Sep 24, 2018
It's one of the few ways to play medical marijuana, but could the move in Corbus Pharmaceuticals continue or is it a smoke screen ...
Off Topic:
Forgot to add this in my post to you.
10/01/2018
Cantor Fitzgerald. Analyst Elemer Piros maintained a Buy rating on Corbus Pharmaceuticals today and set a price target of $36. The company’s shares opened today at $7.68.
Piros said:
“We rate Corbus Pharmaceuticals Overweight. CRBP focuses on the development of a synthetic cannabinoid receptor type 2 (CB2) agonist, lenabasum (JBT-101), for the treatment of rare inflammatory and fibrotic diseases. The company has completed three successful Phase 2 clinical trials in patients with cystic fibrosis (CF) and diffuse cutaneous systemic sclerosis (dcSSc) and dermatomyositis (DM). Valuation Summary We value Corbus based on a risk-adjusted NPV of future cash flows associated with lenabasum. Our 12-month price target is $36/share.”
bigarena, Looks like we are the only 2 here on this message board. LOL
AdvanSource Biomaterials Corp
Unfortunately I can not buy penny stocks in one of my acct`s and do not have enough cash in my TD Ameritrade brokerage acct., so i'll keep an eye on it,thanks.
Thanks i'll check it out. Have another one for you that's in 2 phase 3 trials and is using legal cannabis and just got a patent today. Disruptor play.
$CRBP
Corbus Pharmaceuticals granted U.S. patent related to cannabis Corbus Pharmaceuticals was granted a U.S. patent for ultrapure tetrahydrocannabinol-11-oic acid synthesis, pharmaceutical compositions and methods of use thereof for the treatment and/or prevention of inflammation, pain, and fibrotic diseases including scleroderma, systemic sclerosis, scleroderma-like disorders, sine scleroderma, liver cirrhosis, interstitial pulmonary fibrosis, idiopathic pulmonary fibrosis, Dupuytren's contracture, keloids, chronic kidney disease, chronic graft rejection, and other scarring-wound healing abnormalities, post-operative adhesions, and reactive fibrosis, according to a post to the USPTO site that has been passed among traders. Tetrahydrocannabinol, otherwise known as THC, is the active chemical in cannabis.
obigarena off $TGTX topic,
Wish I had grabbed some yesterday but the charts looked stretched as though it needed some consolidation. Good pick biggarena.
Aurinia Pharmaceuticals: Clear Winner In Lupus Nephritis
Oct. 2, 2018 3:36 PM ET Avisol Capital Partners
https://seekingalpha.com/article/4209457-aurinia-pharmaceuticals-clear-winner-lupus-nephritis
Corbus Pharmaceuticals granted U.S. patent related to cannabis Corbus Pharmaceuticals was granted a U.S. patent for ultrapure tetrahydrocannabinol-11-oic acid synthesis, pharmaceutical compositions and methods of use thereof for the treatment and/or prevention of inflammation, pain, and fibrotic diseases including scleroderma, systemic sclerosis, scleroderma-like disorders, sine scleroderma, liver cirrhosis, interstitial pulmonary fibrosis, idiopathic pulmonary fibrosis, Dupuytren's contracture, keloids, chronic kidney disease, chronic graft rejection, and other scarring-wound healing abnormalities, post-operative adhesions, and reactive fibrosis, according to a post to the USPTO site that has been passed among traders. Tetrahydrocannabinol, otherwise known as THC, is the active chemical in cannabis. Reference Link
Read more at:
https://thefly.com/news.php?symbol=CRBP
Investors conferences may well push this above $10.00 this week with the high short position in the stock.
Event: Cantor Global Healthcare Conference
Date: Monday, October 1, 2018
Time: 2:55 p.m. Eastern Time
Location: InterContinental New York Barclay Hotel, New York, NY
Event: Leerink Partners Roundtable Series: Rare Disease & Oncology
Date: Tuesday, October 2, 2018
Time: 3:00 p.m. Eastern Time
Location: Lotte New York Palace, New York, NY
Looking into Aurinia Pharmaceuticals Inc, thanks.
I don`t generally tout other stocks and this is a little hard to do research on but you might want to have a look at Immtech Pharmaceuticals $IMMP while we are waiting on $TGTX. I`m seeing $IMMP an easy double plus and it's still early and cheap at $4.00 + a share. Trades ADR`s in the U.S. and is Australian listed.
Effective immunotherapy against cancer website
http://www.immutep.com/
Link to research:
https://quotes.wsj.com/IMMP
If you have any good calls please toss them my way, thanks.
Yup, i've $113,703.50 invested throughout the years of accumulating and sleep very sound holding this company. Looking forward to the conferences and Mike to actually shine as he has a lot invested in this too.
Will consider adding more if the damn shorts and algos keep holding the stock down as it does not deserve this low of price with what they have going.
If these conferences don`t light the fire under $TGTX, then we`ll have to wait until we get future trial updates when released. In for the short term and in for the long term either way.
Upcoming events on TG THERAPEUTICS INC
10/01/18 | 02:20pm
Cantor Fitzgerald Global Healthcare Conference
10/02/18 | 01:00pm
Ladenburg Thalmann Healthcare Conference
11/12/18 Q3 2018 Earnings Release (Projected)
03/07/19 FY 2018 Earnings Release (Projected)
Upgrade for October 2nd, 2018
Epizyme analyst commentary at SunTrust Epizyme price target raised to $25 from $20 at SunTrust. SunTrust analyst Peter Lawson raised his price target on Epizyme to $25 and kept his Buy rating, citing the FDA decision for a partial clinical hold lift on tazemetostat enrollment. The analyst notes that the company has not announced any substantial changes to the trial design or patient population, but rather will increase patient monitoring after updating its exclusion criteria for new patient enrollment. Lawson contends that the New Drug Application submission for tazemetostat in the treatment of epithelioid sarcoma expected in the first half of 2019 remains on track.
Dr. Sharman on the Phase III Results of the GENUINE Study in CLL from last year around June 2017 video clip. Tell me $TGTX doesn't have a good science for CLL !!!!!!!!!!!!
Jeff Sharman, MD, medical director, Hematology Research, The US Oncology, discusses the phase III findings of the GENUINE study, the combination of ublituximab (TG-1101) and ibrutinib (Imbruvica) for patients with previously treated high-risk chronic lymphocytic leukemia (CLL).
Click on the insert-text-here
insert-text-here
Or this hyperlink below:
Epizyme: An Updated Investment Thesis
Sep. 26, 2018 4:45 PM ET
https://seekingalpha.com/article/4208450-epizyme-updated-investment-thesis
TG Therapeutics CEO: Market reaction to Unity-CLL drug was 'misplaced,' survival will be better gauge in test
10:39 26 Sep 2018
Progression Free Survival is the primary endpoint of the study and not the Overall Response Rate
The chief executive of TG Therapeutics Inc (NASDAQ:TGTX) said Wednesday the negative reaction to the results of the Unity-CLL Phase 3 trial for treating leukemia was misunderstood by the market when it punished the company's stock harshly in the previous session.
"We believe the market reaction was overblown and misplaced," TG Therapeutics CEO Michael Weiss told Proactive Investors in an email interview. "We can understand that the timelines needed to be adjusted which could cause a modest price decline but the thesis floating around that this news lowers the probability of success of UNITY-CLL is incorrect in our opinion."
The Data Safety Monitoring Board (DSMB) said the results were not sufficient to conduct an Overall Response Rate (ORR) analysis for the drug treating leukemia.
Shares fell to a fresh 52-week low at $5 before recovering to trade just 0.5% down at $5.12 in morning trade. The stock tumbled Tuesday after the news and finished at $5.15.
READ: TG Therapeutics stock sinks after Phase 3 test of leukemia treatment falters, but still has 5 key tests in the pipeline
Weiss said the study for the drug "was designed under the assumption that the driver of improvement in Progression Free Survival (PFS) (is) the primary endpoint for the study."
That is so "because our U2 combination would have a significantly better durability of response not by materially increasing the number of people responding (or ORR). So in essence, even if we had the same number of responders, if each responder in the U2 arm on average survived without progression twice as long as the control arm responders, U2 would be successful in the PFS outcome."
The DSMB seems to bear him out. It said after reviewing the data, there were no safety concerns and recommended the trial continue without any modification.
TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202 (umbralisib), an orally available PI3K delta inhibitor for various hematologic malignancies.
Weiss said the study was crafted "so those endpoints would be assessed independently and the success of one was not contingent on the success of the other. Had we believed that PFS was contingent on a large difference in ORR, we would have designed the study statistically to reflect that, but we did not. We believe this point has been misunderstood by the street."
TG Therapeutics said the success of the drug's test should be focused on patient survival because "PFS is the gold standard for the FDA."
"Certainly, patients care about living longer without progressive disease. Our drug, umbralisib, is from a class of drugs that are known to provide enhanced PFS and also are known to keep the disease in check versus killing it quickly. So certainly, under the circumstances, PFS is the endpoint that can really showcase the benefit our drug has for patients," said Weiss.
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is based In New York City.
http://www.proactiveinvestors.com/companies/news/205781/tg-therapeutics-ceo-market-reaction-to-unity-cll-drug-was-misplaced-survival-will-be-better-gauge-in-test-205781.html
Looking forward to the conferences which should lead to more clarification on the trials.
I added another 2000 today too. Only thing that's changed is timeline. GL
Funny how investors are reacting as if the trial failed. It's still ongoing plus the other trials, but now the shorts are out in full force. Time to consider adding again at these levels. GLA in your decisions to buy/sell and hold..
Another good read.
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2241751/#!po=0.0574713
Some good reading on fly on the wall latest news....
Corbus Pharmaceuticals analyst commentary at JMP Securities Corbus deal for endocannabinoid compounds makes sense, says JMP Securities. JMP Securities analyst Liisa Bayko said she is pleased with Corbus' announcement that it has licensed the exclusive worldwide rights to develop, manufacture and market drug candidates from more than 600 compounds targeting the endocannabinoid system from Jenrin. While she thinks the deal "makes a lot of strategic sense," Bayko is not yet incorporating the drug candidates into her valuation given the early stage of these assets. Bayko, who said the new assets represent potential upside, keeps an Outperform rating and $27 price target on Corbu
https://thefly.com/news.php?symbol=CRBP
I seriously do not understand why other message boards think this is a negative interview. You might dislike Cramer but the message from the CEO is nothing but spot on positive. It got me to finally invest and i`ve had this company on my radar for years.
'We're ahead of the pack' in the cannabinoid drug space, says CEO
6:51 PM ET Thu, 20 Sept 2018
Jim Cramer sits down with Yuval Cohen, the CEO of a company that is creating treatments derived from man made cannabinoids for rare diseases like cystic fibrosis.
https://www.cnbc.com/video/2018/09/20/corbus-pharma-ceo-were-ahead-of-the-pack-in-cannabinoid-therapies.html
Don`t need no stinking pot stocks........
Synthetic THC and enough money in the coffers.
News algo`s playing here but this can trade up well on its own....
Took first position today as the company will become more widely known. Will add on dips........as this will become a disruption play.
“More and more big pharma companies are going to turn their attention to this completely untapped biological system,” Cohen said. “The advantages we have as Corbus—our vision, our nimbleness and now, our patent portfolio—put us ahead of the pack.”
WHY TG THERAPEUTICS INC COMMON STOCK (NASDAQ:TGTX) MAY BE ON THE VERGE OF SOME FIREWORKS
Sep 18, 2018 | Business
We are always particularly interested to see stocks like TG Therapeutics Inc common stock (NASDAQ:TGTX) take a tumble with no obvious catalyst, especially when the stock is closing in on some important topline data revelations, as is the case here. Management noted back in June that the topline response rate data from the UNITY-CLL Phase 3 trial would be released “by the end of summer 2018.” However, here we are, within days of the fall equinox, and nothing yet. Shares are diving perhaps on nerves that the results will be delayed or somehow confounded. But that could also be a headfake in the making with some remarkable upside potential in coming days.
In addition, the story here is really about a potential powerhouse pipeline that has more depth than just this latest data. The company is developing two therapies targeting hematological malignancies and autoimmune diseases. Ublituximab (TG-1101) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing umbralisib (TGR-1202), an orally available PI3K delta inhibitor. Both ublituximab and umbralisib, or the combination of which is referred to as “U2”, are in Phase 3 clinical development for patients with hematologic malignancies, with ublituximab also in Phase 3 clinical development for Multiple Sclerosis.
TG Therapeutics Inc common stock (NASDAQ:TGTX) bills itself as a biopharmaceutical company that focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases in the United States.
TGTX has a significant war chest ($126.2M) of cash on the books, which compares with about $36.9M in total current liabilities. One should also note that debt has been growing over recent quarters. TGTX is pulling in small trailing 12-month revenues of $152K. But the pipeline is the story here.
Traders will note just shy of -20% stripped out of share pricing for the listing in the past month. The selling has accelerated in recent action on climbing average volume, with an increase in recent trading volume of 71% over the long run average.
Under the Hood
The company develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory chronic lymphocytic leukemia.
The company also develops TGR-1202, an orally available phosphoinositide-3-kinase delta inhibitor with nanomolar potency to the delta isoform and high selectivity over the alpha, beta, and gamma isoforms, as well as for hematologic malignancies. In addition, it develops a pre-clinical program to develop interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors; bromodomain and extra terminal (BET) inhibitor program for cancer treatment; and anti-PD-L1 and anti-GITR antibody research programs that are in pre-clinical development stage in the field of hematological malignancies.
The company has license agreements with LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, and Ildong Pharmaceutical Co. Ltd. for the development and commercialization of TG-1101 (ublituximab); Rhizen Pharmaceuticals, SA for the development and commercialization of TGR-1202; Ligand Pharmaceuticals Incorporated for the development and commercialization of IRAK4 inhibitor technology; Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs; and Jubilant Biosys for the development and commercialization of BET inhibitor program.
Earning a current market cap value of $746.61M, this may be a very interesting story and we will look forward to updating it again soon.
https://fdaheadlines.com/why-tg-therapeutics-inc-common-stock-nasdaqtgtx-may-be-on-the-verge-of-some-fireworks/
Too coincidental and very interesting. $ABBV could be the perfect partner for either yet $VSTM has little pipeline compared to $TGTX.
Still no idea what Management filed it for but this helps some.
Confidential Treatment Order - CTO
What is a 'Confidential Treatment Order - CTO'
A confidential treatment order (CTO) is an order that provides confidential treatment for certain documents and information that a company would otherwise have to file with the Securities and Exchange Commission (SEC). A confidential treatment order is issued by the SEC and may only be in effect for a certain period of time. If a company wishes to omit certain information from their required filings they can complete a confidential treatment order request, which is reviewed by the SEC. The request must contain the information the company is looking to withhold and the time period the company is looking to withhold the information. This includes providing a date upon which the CTO would expire. Only certain types of information can be held confidential and the requesting company must provide evidence that disclosure of the information would provide it competitive harm.
CONFIDENTIAL TREATMENT APPLICATION
NATIONAL TREATMENT
FORM 2848: POWER OF ATTORNEY AND ...
CAPITAL GAINS TREATMENT
BREAKING DOWN 'Confidential Treatment Order - CTO'
Companies would typically seek a confidential treatment order (CTO) to keep information secret that would otherwise put it at a competitive disadvantage if revealed. A company would seek the confidential treatment order by filing a formal request, a confidential treatment request (CTR), with the Securities and Exchange Commission (SEC).
Example of a Confidential Treatment Order
For example, a company may apply for a confidential treatment order by completing a confidential treatment request to keep information regarding a pricing arrangement made with a potential acquisition target secret. This request could be made on the basis that the company's competitors may use this information to go after the target with a more competitive price. Other common items kept confidential include milestone payments and other technical specifications.
That may be. I wonder if this was the cause of all the BS selling and it leaked so shorts overwhelmed the buyers that would take this as more delay somehow.
I've had a core position for 5 + years and a trading position that I have had to add to on this downturn to average out my cost basis.
I seriously believe $TGTX is striving for good trial outcomes and any delay is a necessity for the long term. $TGTX has had some excellent science and trial outcomes for some very difficult complications.
I've had the pleasure to communicate with some people in the CLL trials that are alive today that otherwise had no other options. You may of read some of their posts on other message boards supporting $TGTX.
Finally this has been one of the most underrated manipulated bio I have ever held and don't expect the noise to end. I`ll keep posting the good and the bad as there is alway two sides to the story until truth be told!
Looks like this filing may be the hold up but could be very positive and if leaked was the reason for the past days of heavy shorting.
I read nothing negative into this just $TGTX coving some very good intellectual property. Thoughts anyone?????????
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
September 18, 2018
ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES EXCHANGE ACT OF 1934
TG Therapeutics, Inc.
File No. 1-32639 - CF#36670
_____________________
TG Therapeutics, Inc. submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 10-Q filed on August 9, 2018.
Based on representations by TG Therapeutics, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit will not be released to the public for the time period specified:
Exhibit 10.20 through August 8, 2021
For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:
Brent J. Fields
Secretary
http://ir.tgtherapeutics.com/sec-filings/sec-filing/ct-order/9999999997-18-007926
This is a pretty fair assessment of our current situation.
Note: I`ve been adding shares all month and in the past week plus today.
Vantage Logo September 18, 2018
Slowly, TG investors start to fear the worst
http://www.evaluate.com/vantage/articles/news/slowly-tg-investors-start-fear-worst
AbbVie $ABBV could be weighing on $TGTX of late not to mention $VSTM
Verastem, Inc. also but still like $TGTX even more in the single digits as it has a good pipeline.....
Your Cancer Highlight: AbbVie Quietly Aims For A New Best-In-Class Approval In CLL
Sep. 18, 2018 8:00 AM ET|18 comments | About: AbbVie Inc. (ABBV), Includes: JNJ, RHHBF
Zach Hartman
Zach Hartman
Biotech, healthcare, Deep Value, contrarian
Invest Against Cancer
Summary
AbbVie and partner Janssen quietly announced an important submission.
The implications for CLL management are clear, and they signal a tighter weaving of one of their main drugs into the standard of care.
It's also a signal that we should pay attention to ASH this year for CLL.
Please note that I am affiliated with Avisol Capital Partners and their Total Pharma Tracker service. They have also covered the companies in this article in their writings, and I wanted to make readers aware of the potential for overlapping coverage.
Treatment of chronic lymphocytic leukemia (CLL) has come a very long way in just a few years, with the introduction of an array of new therapeutic options. Arguably, the most notable of these new options would be the emergent small molecule targeted therapies, particularly the Bruton's tyrosine kinase inhibitor ibrutinib and the Bcl-2 inhibitor venetoclax, both now owned by AbbVie (ABBV).
Specifically, ibrutinib has made a meteoric impact on the management of CLL, offering one of the first chances we've had for patients with high-risk disease features, along with the opportunity to replace chemotherapy for patients who are frail.
Needless to say, ABBV and their partner Johnson and Johnson (JNJ) have been working diligently to get ibrutinib weaved throughout the entire continuum of care for CLL, wherever it may fit. Thus, ibrutinib is now approved in the following indications:
Monotherapy treatment in CLL
Monotherapy treatment in CLL, specifically for patients with 17p deletion (a high-risk disease feature that is associated with poor responses to traditional therapy)
These approvals can restrict the use of ibrutinib to those patients who do not have aggressive disease (and hence no need for aggressive, multiagent therapy), for those who relapsed on chemotherapy, or for those who are not suitable candidates for chemotherapy (either due to high-risk disease features or old age/comrbidities).
As such, ABBV and JNJ have turned a lot of their attention toward exploring ibrutinib as part of different combinations, particularly with the goal of substituting chemotherapy for ibrutinib to arrive at a less toxic, more effective treatment regimen.
The news
Although it was not announced, ABBV's partner Janssen (of Johnson & Johnson) divulged during its Q3 business update that the first-line combo of ibrutinib and obinutuzumab had been submitted to the FDA for approval.
Therefore, it's likely that we're going to see some kind of news about the acceptance of this application. I'm not sure if it could get priority review, but this application sets a timeline for approval sometime in 2019.
Interestingly, the company also divulged its intentions to submit applications for approval in other indications, including in combination with rituximab for first-line therapy, as well as used as monotherapy in patients with higher-risk early-stage disease (where they would normally be managed by "watch and wait").
Looking forward
The application for approval was supported by findings from the iLLUMINATE study, a phase 3 trial comparing chlorambucil-obinutuzumab to ibrutinib-obinutuzumab for patients with CLL who had no prior exposure to therapy. We know from an announcement from JNJ and ABBV from earlier this year that iLLUMINATE met its primary endpoint of improved progression-free survival.
We have yet to see the full results of this study, but I expect they'll be coming at this year's ASH meeting. Even so, it's difficult to imagine that ABBV and JNJ will fail to get this approval, given the fact that the combination improved PFS, making it another opportunity to land an effective "chemotherapy-free" treatment regimen into the treatment landscape.
Moreover, it helps to build Roche's (OTCQX:RHHBF) credibility in an era where biosimilars will start to eat into rituximab sales. We could very well end up seeing a new standard of care emerge for those patients who are not suitable recipients of chemotherapy. Without a doubt, it would mean a continued domination of the CLL treatment space on the part of ABBV and JNJ.
While it wouldn't likely supplant chemoimmunotherapy for healthier, younger patients (under the age of 65 years), ibrutinib-obinutuzumab could well become a major contender for older patients. Considering CLL is a cancer particularly of old age (median age of diagnosis 72 years), this is no small thing, and currently chlorambucil-obinutuzumab is a major treatment option in this patient population, with a Category 1 recommendation from the NCCN.
Overall, this submission and subsequent approval (assuming it goes through) could very well be a game changer in the space, and discerning investors definitely need to keep an eye out for a formal presentation of the iLLUMINATE study later this year.
This quiet news is a definite signal that ABBV continues to build major inroads across the treatment landscape for CLL, and when it comes to replacing their aging blockbusters, this may be one of their major paths forward.
Thank you for taking some time out of your day to read this article! If you liked what you see, I hope you'll consider becoming a follower of mine on Seeking Alpha, as this will allow you to get real-time notifications when new articles of mine go live. Also, I want to let you know that I am a regular contributor to the Total Pharma Tracker, a marketplace service run by Avisol Capital Partners. If you want to join our conversations about biotech stocks, consider taking part in a free two-week trial today!
Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Editor's Note: This article discusses one or more securities that do not trade on a major U.S. exchange. Please be aware of the risks associated with these stocks.
https://seekingalpha.com/article/4206839-cancer-highlight-abbvie-quietly-aims-new-best-class-approval-cll
Viral hit Tweet leads to excellent last great buying opportunity.....
Does not help that it is consistently sold down on small tardes and volume daily. If it is over $1.00 going into the close of trade, it will be sold down.
To track time and sale daily:
https://quotes.freerealtime.com/quotes/APHB/Time&Sales
Interesting opinion from this DR. on his twitter feed for $TGTX:
Private Doctor/Investor specializing in micro/small cap biotech-big believer in collaborative networks of fellow investors who can & do beat the institutions
https://twitter.com/BillMiller32
Trial study, updated Sept. 6th:
Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 With or Without Bendamustine and TGR-1202 Alone in Patients With Previously Treated Non-Hodgkins Lymphoma (UNITY-NHL)
https://clinicaltrials.gov/ct2/show/record/NCT02793583
Started, first buy entry today. This could be hugh going forward.
Is Aphria Going to Be Chosen as Diageo’s Canadian Cannabis Partner?
Alcohol, pharma, tobacco companies on the prowl and we are still early on in this disruptive industry................
Interesting article:
UN Reviewing Marijuana’s Place With International Drug Treaties
The UN could force the US Government to reconsider Marijuana's Schedule I classification.
Just two months after the U.N.’s World Health Organization published a report calling marijuana a “relatively safe drug” that only seems to lead to “euphoria, laughter and talkativeness,” the intergovernmental organization as a whole is reportedly diving in to determine whether it is even necessary to restrict the herb under international law. The outcome could force the United States to reconsider marijuana’s Schedule I classification on the Controlled Substances Act, according to a report from Marijuana Moment.
In June, the WHO’s Expert Committee on Drug Dependence (ECDD) found that cannabis is a “relatively safe drug” and not substance that has the power to lead to fatal overdoses. It went on to explain that there is very little evidence pointing to the herb as a threat to cardiovascular health, and it even suggested that marijuana had the ability to slow the growth of cancer cells.
Most of the health concerns related to cannabis consumption, the reports states, are from smoking. But “increasing use of vaporizers and other non-smoking modes of delivery is likely to reduce” health complications.
Overall, WHO said the only adverse reactions of marijuana are “euphoria, laughter and talkativeness.”
In response to that report, WHO Director-General Tedros Adhanom Ghebreyesus wrote this week that, “The Committee recommended that preparations considered to be pure CBD should not be scheduled within the International Drug Control Conventions” and that “there is sufficient evidence to proceed to a Critical Review” of all things marijuana.
The organization will conduct its first-ever in-depth review of the cannabis plant in November. Scientific experts will look at the chemistry, pharmacology, toxicology, epidemiology, and therapeutic use of marijuana to determine if it belongs under international control.
“This initial evaluation is also an opportunity to identify gaps in the available scientific data,” a WHO document reads. “A critical review is carried out when there is sufficient scientific evidence to allow the ECDD to make informed an recommendation that the substance be placed under international control, or if its level of control should be changed.”
Essentially, the U.N. plans to look at both CBD and THC to make a determination as to whether the compounds still fit the dangerous drug criteria as outlined in the international drug treaties.
“Several countries permit the use of cannabis for the treatment of medical conditions such as back pain, sleep disorders, depression, post-injury pain, and multiple sclerosis,” the document reads. “The evidence presented to the Committee did not indicate that cannabis plant and cannabis resin were liable to produce ill-effects similar to these other substances that are in Schedule IV of the 1961 Convention on Narcotic Drugs. The inclusion of cannabis and cannabis resin in Schedule IV may not appear to be consistent with the criteria for Schedule IV.”
If the U.N. moves to change the status of the cannabis plant, the United States government would be required to review its Schedule I status.
https://mjobserver.com/politics/un-reviewing-marijuanas-place-with-international-drug-treaties/
Is the Options Market Predicting a Spike in TG Therapeutics (TGTX) Stock?
Investors in TG Therapeutics, Inc. TGTX need to pay close attention to the stock based on moves in the options market lately. That is because the Sep 21, 2018 $18 Call had some of the highest implied volatility of all equity options today.
What is Implied Volatility?
Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.
What do the Analysts Think?
Clearly, options traders are pricing in a big move for TG Therapeutics shares, but what is the fundamental picture for the company? Currently, TG Therapeutics is a Zacks Rank #3 (Hold) in the Medical - Products industry that ranks in the Bottom 35% of our Zacks Industry Rank. Over the last 60 days, one analyst has increased its earnings estimates for the current quarter, while two analysts have dropped their estimates. The net effect has taken our Zacks Consensus Estimate for the current quarter from a loss of 52 cents per share to a loss of 54 cents in that period.
Given the way analysts feel about TG Therapeutics right now, this huge implied volatility could mean there’s a trade developing. Often times, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.
https://finance.yahoo.com/news/options-market-predicting-spike-tg-123912195.html